Author

M. Felices

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:genetic perturbation / CRISPR· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

B. R. Webber· 2 shared B. S. Moriarity· 2 shared B. Walcheck· 2 shared E. J. Pomeroy· 2 shared J. S. Miller· 2 shared C. E. Thefaine· 1 shared G. T. Hart· 1 shared J. A. Sangala· 1 shared

Activity by Year

2018-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

B. R. Webber

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Ablation of SYK kinase from primary human Natural Killer cells via CRISPR/Cas9 enhances cytotoxicity and cytokine production

J. D. Dahlvang, J. K. Dick, J. A. Sangala, E. J. Pomeroy, K. M. Snyder, J. M. Moushon, C. E. Thefaine, J. Wu, S. E. Hamilton, M. Felices, J. S. Miller, B. Walcheck, B. R. Webber, B. S. Moriarity, G. T. Hart

This study ablates SYK kinase in primary human NK cells using CRISPR/Cas9, finding it enhances cytotoxicity and cytokine production compared to other gene ablations.

bioRxiv · May 29, 2022 · PreprintImmunology

A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy

E. J. Pomeroy, J. T. Hunzeker, M. T. Kluesner, M. R. Crosby, W. S. Lahr, L. Bendzick, J. S. Miller, B. R. Webber, M. A. Geller, B. Walcheck, M. Felices, T. K. Starr, B. S. Moriarity

This paper develops a CRISPR/Cas9-based method to edit human NK cells, enhancing their anti-cancer activity by knocking out ADAM17 and PD1.

bioRxiv · Sep 29, 2018Immunology